Sol-Gel Technologies (SLGL)

• Market cap: $212M
• 1 day: -4.7%
• 5 days: -20.83%
• 1 month: -6.18%
• 3 months: 77.78%
• 6 months: 186.04%
• Year to date: 80.31%
• 1 year: 1,257.14%
• 5 years: -39.2%
• 10 years: -44.28%
• Sector: Healthcare
• Industry: Biotechnology

About: Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.

Employees: 34